Key Publications

In vitro antibacterial properties of pexiganan, an analog of magainin.
Ge Y, MacDonald DL, Holroyd KJ, Thornsberry C, Wexler H, Zasloff M. Antimicrob Agents Chemother. 1999Apr;43(4):782-8.

In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers.
Ge Y, MacDonald D, Henry MM, Hait HI, Nelson KA, Lipsky BA, et al. Diagn Microbiol Infect Dis.1999b Sep;35(1):45-53.

In Vitro Spectrum of Pexiganan Against Pathogens from Diabetic Foot Infections and with Selected Resistance Mechanisms - ICAAC 2014
RK Flamm, PR Rhomberg, KM Simpson, DJ Farrell, HS Sader, RN Jones - JMI Laboratories, North Liberty, Iowa, USA

In Vitro Spectrum of Pexiganan Activity when Tested Against Pathogens from Diabetic Foot Infections and with Selected Resistance Mechanisms – Journal Publication
RK Flamm, PR Rhomberg, KM Simpson, DJ Farrell, HS Sader, RN Jones - JMI Laboratories, North Liberty, Iowa, USA

In Vitro Activity of Pexiganan Tested Against Pathogens with Elevated MICs to Topical Antimicrobials - ICAAC/ICC 2015
RK Flamm, PR Rhomberg, DJ Farrell, RN Jones - JMI Laboratories, North Liberty, Iowa, USA

In Vitro Activity of Pexiganan and 8 Comparator Antimicrobials against 234 Isolates Including 93 Pasteurella spp. and 50 Anaerobic Bacteria Recovered from Animal Bite Wounds - ASM Microbe 2016
EJC Goldstein, DM Citron, KL Tyrrell, E Leoncio - RM Alden Research Laboratory, Culver City, CA

In Vitro Activity of Pexiganan and Ten Comparator Antimicrobials Against 503 Anaerobic Bacteria Recovered from Skin and Skin Structure Infections - ASM Microbe 2016
DM Citron, KL Tyrrell, E Leoncio, EJC Goldstein - RM Alden Research Laboratory, Culver City, CA

Antimicrobial Peptides and Wound Healing; Biological and Therapeutic Considerations
Mangoni ML, McDermott AM, and Zasloff M Experimental Dermatology 2016, 25, 167–173

Structure, membrane orientation, mechanism, and function of pexiganan - a highly potent antimicrobial peptide designed from magainin.
Gottler LM, Ramamoorthy, A. Biochim Biophys Acta. 2009 Aug;1788(8):1680-6.

Membrane Pores Induced by Magainin
Steve J. Ludtke, Ke He, William T. Heller, Thad A. Harroun, Lin Yang, and Huey W. Huang Biochemistry 1996, 35, 13723-13728

Structure-activity studies on magainins and other host defense peptides.
Maloy WL, Kari UP. Biopolymers. 1995;37(2):105-22.

Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor.
Zasloff M. Proc Natl Acad Sci U S A. 1987 Aug;84(15):5449-53.

Antimicrobial peptides of multicellular organisms.
Zasloff M. Nature. 2002 Jan 24;415(6870):389-95.

Antimicrobial activity of synthetic magainin peptides and several analogues.
Zasloff M, Martin B, Chen HC. Proc Natl Acad Sci USA. 1988 Feb;85(3):910-3.

2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections
Benjamin A. Lipsky, Anthony R. Berendt, Paul B. Cornia, James C. Pile, Edgar J. G. Peters, David G. Armstrong, H. Gunner Deery, John M. Embil, Warren S. Joseph, Adolf W. Karchmer, Michael S. Pinzur, and Eric Senneville CID 2012:54 (15 June)

IDSA Guidelines 2004; Diagnosis and treatment of diabetic foot infections.
Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, et al. Clin Infect Dis. 2004 Oct 1;39(7):885-910.

Validation of the Infectious Diseases Society of America's diabetic foot infection classification system.
Lavery LA, Armstrong DG, Murdoch DP, Peters EJ, Lipsky BA. Clin Infect Dis. 2007 Feb 15;44(4):562-5.

Topical antimicrobial therapy for treating chronic wounds.
Lipsky BA, Hoey C. Clin Infect Dis. 2009 Nov 15;49(10):1541-9.

Antimicrobial Agents for Complicated Skin and Skin-Structure Infections: Justification of Noninferiority Margins in the Absence of Placebo-Controlled Trials
Brad Spellberg, George H. Talbot, Helen W. Boucher, John S. Bradley, David Gilbert, W. Michael Scheld, John Edwards, Jr. Clinical Infectious Diseases 2009; 49:383–91

A systematic review of the effectiveness of interventions in the management of infection in the diabetic foot
E. J. G. Peters, B. A. Lipsky, A. R. Berendt,, J. M. Embil, L. A. Lavery, E. Senneville, V. Urbanۍiۍ-Rovan K. Bakker, W. J. Jeffcoate Diabetes Metab Res Rev 2012; 28(Suppl 1): 142–162. Published online in Wiley Online Library (wileyonlinelibrary. com) DOI:10.1002/dmrr.2247

Expert opinion on the management of infections in the diabetic foot (IWGDF)
B. A. Lipsky, E. J. G. Peters, E. Senneville, A. R. Berendt, J. M. Embil, L. A. Lavery, V. Urbančič-Rovan, W. J. Jeffcoate Diabetes Metab Res Rev 2012; 28(Suppl 1): 163-178. Published online in Wiley Online Library (wileyonlinelibrary. com) DOI:10.1002/dmrr.2248

Specific guidelines for the treatment of diabetic foot infections 2011( IWGDF)
B. A. Lipsky, E. J. G. Peters, A. R. Berendt, E. Senneville, K. Bakker, J. M. Embil, L. A. Lavery, V. Urbančič-Rovan Diabetes Metab Res Rev 2012; 28(Suppl 1): 234–235. Published online in Wiley Online Library (wileyonlinelibrary. com) DOI:10.1002/dmrr.2251